立體定位消融（身體）放射治療（SABR or SBRT）對早期肺癌而言是一個標準治療 方法之一，甚至是目前最佳的非手術治療 [14] 。雖然缺少第3 期隨機分派研究，在少 數的整合分析的資料中，其中有一篇以 2 年 與 5 年的全部存活率與針對疾病的存活率來 作評斷依據，證實了 SABR 較傳統的放射治 療為佳 [7] 。許多回溯性與第 1-2 期研究已 證實這種治療在 2-3 年後可以得到超過 90% 的局部控制 [19, 22, 23] 。RTOG 0236 研究 包括了 59 位 cT1-2N0M0 非小細胞肺癌的病 患，3 年局部控制率與局部區域控制率各自 為 90.6% 與 87.2% [23] 。Senthi et al. 在 2012 年發表了關於 SABR 最大型的回溯性研究 [19] ，他們分析了 676 位病患，2 年局部復 發率，區域復發率，與遠端復發率各自為 4.9% 、7.8% 、14.7%。

Stereotactic ablative (body) radiotherapy (SABR or SBRT) for early stage non-small cell lung cancer (NSCLC) is one of the standard treatments and probably the best current nonsurgical treatment [14]. Until now there has been no phase three randomized trial. However, data from a meta-analysis confirmed that SABR gives better results than conventional radiotherapy in overall and disease-specific survival rates at 2- or 5-years, respectively [7]. Many retrospective and phase I/II studies had demonstrated that this treatment could yield more than 90% of local control at two or three years [19, 22, 23]. The RTOG 0236 trial included 59 cT1-2N0M0 non-small cell lung cancer patients. The 3-year local and localregional control rates were 90.6% and 87.2%, respectively [23]. Senthi el al. [19] reported the world largest retrospective SABR study in 2012. They analyzed 676 cases and the 2-year local, regional, and distant recurrent rates were 4.9, 7.8, and 14.7%, respectively.